Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new…
Danish biopharmaceutical company Breye Therapeutics has secured €67.5 million in Series A funding to advance its oral therapies for early treatment of retinal diseases. The round was led by Mission BioCapital and co-led by existing investor Novo Holdings, with participation from other new investors such as the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital.
The funding will enable Breye to progress its pioneering oral treatment, danegaptide, for diabetic retinopathy to the next stage of clinical development. The CEO, Ulrik Mouritzen, highlighted the financing as a major milestone, reflecting strong confidence in the company's vision and pipeline. Danegaptide is a first-in-class oral small molecule with a novel mechanism of action that stabilises retinal vasculature, offering a patient-friendly treatment option for diabetic retinopathy, which affects about 130 million people worldwide.
Brief written by urgent.news from EU-Startups's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
